Press coverage about TESARO (NASDAQ:TSRO) has been trending somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TESARO earned a news impact score of 0.05 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.2085504387662 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

TESARO (NASDAQ:TSRO) opened at $61.96 on Wednesday. TESARO has a 52-week low of $55.02 and a 52-week high of $192.94. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73. The firm has a market capitalization of $3,360.00, a P/E ratio of -7.35 and a beta of 1.25.

Several research firms have weighed in on TSRO. Zacks Investment Research cut TESARO from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. HC Wainwright reiterated a “buy” rating and issued a $158.00 price objective on shares of TESARO in a report on Monday, November 20th. Cowen dropped their price objective on TESARO from $125.00 to $80.00 and set a “market perform” rating for the company in a report on Tuesday, January 2nd. SunTrust Banks reiterated a “buy” rating and issued a $160.00 price objective on shares of TESARO in a report on Friday, November 10th. Finally, Piper Jaffray Companies reiterated a “neutral” rating and issued a $117.00 price objective on shares of TESARO in a report on Monday, October 23rd. Three analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $149.97.

In related news, SVP Martin H. Jr. Huber sold 829 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $85.24, for a total transaction of $70,663.96. Following the completion of the transaction, the senior vice president now owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 34.60% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “TESARO (TSRO) Receives Media Impact Score of 0.05” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at


TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with's FREE daily email newsletter.